Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANER study of neratinib diarrhea prophylaxis strategies in early HER2-positive, hormone receptor-positive breast cancer
2024-514630-21-00Phase 2Authorised
- Sponsor
- GEICAM
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of neratinib, loperamide and colesevelam in breast cancer (3 arms), sponsored by GEICAM. Primary endpoint: Incidence of neratinib discontinuations due to diarrhea at the end of 3 cycles of neratinib treatment. Planned start Nov 2024; status: authorised.
02
Drugs
neratinibloperamidecolesevelam
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514630-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514630-21-00.